

- 163 -

Claims

1. Glycinamide derivatives of formula I

5

A-D-B

(I)

wherein

10

D is a bivalent glycine amide moiety, or a derivative thereof,

15

A is a unsubstituted or substituted moiety of up to 40 carbon atoms of the formula: $-L-(M-L')_{\alpha}$, where L is a 5, 6 or 7 membered cyclic structure, preferably selected from the group consisting of aryl, heteroaryl, arylene and heteroarylene, bound directly to D, L' comprises an optionally substituted cyclic moiety having at least 5 members, preferably selected from the group consisting of aryl, heteroaryl, aralkyl, cycloalkyl and heterocyclyl, M is a bond or a bridging group having at least one atom, α is an integer of from 1-4; and each cyclic structure of L and L' contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L' is preferably substituted by at least one substituent selected from the group consisting of $-SO_pR_x$, $-C(O)R_x$ and $-C(NR_y)R_z$.

20

25

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms, preferably of up to 20 carbon atoms, comprising at least one 5-, 6-, or 7-membered cyclic structure, preferably a 5- or 6-membered cyclic structure, bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein said cyclic structure directly bound to D is preferably selected from the group

30

- 164 -

consisting of aryl, heteroaryl and heterocyclyl, R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

5

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

10

R_x is R_z or NR_aR_b , where R_a and R_b are

15

a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

20

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

25

30

or

- 5 b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- 10 c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of
- 15 halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
- 20 where B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_γ , where γ is 0-3;
- 25 wherein each W is independently selected from the group consisting of $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, $-Q-Ar$, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the groups
- 30 consisting of $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, -

- 166 -

$\text{NR}^5\text{C}(\text{O})\text{R}^5$ and halogen up to per-halo; with each R^5 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N(R^5)-, -(CH_2) β -, -C(O)-, -CH(OH)-, -(CH_2) β O-, -(CH_2) β S-, -(CH_2) β N(R^5)-, -O(CH_2) β -, -CHHal-, -CHal $_2$ -, -S-(CH_2)- and -N(R^5)(CH_2) β - where $\beta = 1-3$, and Hal is halogen; and Ar is 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by $\text{Z}_{\delta 1}$ wherein $\delta 1$ is 0 to 3 and each Z is independently selected from the group consisting -CN, -CO $_2\text{R}^5$, -C(O)NR $^5\text{R}^5$, -C(O)-R 5 , -NO $_2$, -OR 5 , -SR 5 , -SO $_2\text{R}^5$, -SO $_3\text{H}$, -NR $^5\text{R}^5$, -NR $^5\text{C}(\text{O})\text{OR}^5$, -NR $^5\text{C}(\text{O})\text{R}^5$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO $_2\text{R}^5$, -C(O)NR $^5\text{R}^5$, -C(O)-R 5 , -NO $_2$, -OR 5 , -SR 5 , -SO $_2\text{R}^5$, -SO $_3\text{H}$, -NR $^5\text{R}^5$, -NR $^5\text{C}(\text{O})\text{OR}^5$, -NR $^5\text{C}(\text{O})\text{R}^5$, and the the physiologically acceptable derivatives, salts and solvates thereof.

2. Glycinamide derivative according to claim 1, characterised in that each M independently from one another represents a bond or is a bridging group, selected from the group consisting of (CR $^5\text{R}^5$) $_h$, or (CHR 5) $_h$ -Q-(CHR 5) $_l$, wherein

Q is selected from a group consisting of O, S, N-R 5 , (CHal $_2$) $_j$, (O-CHR 5) $_j$, (CHR 5 -O) $_j$, CR 5 =CR 5 , (O-CHR 5 CHR 5) $_j$,

- 167 -

$(\text{CHR}^5\text{CHR}^5\text{-O})_j$, C=O , C=S , C=NR^5 , $\text{CH(OR}^5\text{)}$, $\text{C(OR}^5\text{)(OR}^5\text{)}$,
 C(=O)O , OC(=O) , OC(=O)O , $\text{(C=O)N(R}^5\text{)C(=O)}$, $\text{OC(=O)N(R}^5\text{)}$,
 $\text{N(R}^5\text{)C(=O)O}$, CH=N-NR^5 , S=O , SO_2 , SO_2NR^5 and NR^5SO_2 ,
 wherein

5

R^5 is in each case independently selected from the meanings given
 above, preferably hydrogen, halogen, alkyl, aryl, aralkyl,


10

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6,
 preferably 0, 1, 2 or 3, and

j is 1, 2, 3, 4, 5 or 6, preferably 0, 1, 2 or 3.

15

3. Glycinamide derivative according to claim 1 or 2, selected from the
 compounds of formula II,



II

20

wherein

25

Ar^1, Ar^2 are selected independently from one another from
 aromatic hydrocarbons containing 6 to 14 carbon atoms
 and ethylenical unsaturated or aromatic heterocyclic
 residues containing 3 to 10 carbon atoms and one or two
 hetero atoms, independently selected from N, O and S,

30

R^8, R^9
 and R^{10} are independently selected from a group
 consisting of H, A, cycloalkyl comprising 3 to 7 carbon
 atoms, Hal, CH_2Hal , CH(Hal)_2 , C(Hal)_3 , NO_2 , $(\text{CH}_2)_n\text{CN}$,

- 168 -

$(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$,
 $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$,
 $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$,
 $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$,
 $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$,
 $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$,
 $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,
 $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$,
 $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$,
 $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{11}$,
 $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$,
 $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$,
 $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$,
 $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$,
 $(CH_2)_nN(CH_2CONH_2)COOR^{11}$,
 $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$,
 $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$
 and $(CH_2)_nNCO$, wherein

R^{11} , R^{12} are independently selected from a group consisting of H,
 A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,

R^{11} and R^{12} form, together with the N-Atom they are bound to,
 a 5-, 6- or 7-membered heterocyclus which optionally
 contains 1 or 2 additional hetero atoms, selected from
 N, O and S,

R^{13} , R^{14} are independently selected from a group consisting of H,
 Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from the group consisting of alkyl, alkenyl,
 cycloalkyl, alkylencycloalkyl, alkoxy and alkoxyalkyl,

- Ar³, Ar⁴ are independently from one another aromatic hydrocarbon residues comprising 5 to 12 and preferably 5 to 10 carbon atoms which are optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,
- Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,
- R¹⁵, R¹⁶ are independently selected from a group consisting of H, A, and (CH₂)_mAr⁵, wherein
- Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,
- n, m are independently of one another 0, 1, 2, 3, 4, or 5;
- X represents a bond or is (CR¹¹R¹²)_h, or (CHR¹¹)_h-Q-(CHR¹²)_i, wherein
- Q is selected from a group consisting of O, S, N-R¹⁵, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵),

- 170 -

$C(OR^{17})(OR^{20})$, $C(=O)O$, $OC(=O)$, $OC(=O)O$, $C(=)N(R^{15})$,
 $N(R^{15})C(=O)$, $OC(=O)N(R^{15})$, $N(R^{15})C(=O)O$, $CH=N-O$,
 $CH=N-NR^{15}$, $OC(O)NR^{15}$, $NR^{15}C(O)O$, $S=O$, SO_2 , SO_2NR^{15}
 und $NR^{15}SO_2$, wherein

5

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

j is 1, 2, 3, 4, 5 or 6,

10

Y is selected from O, S, NR^{21} , $C(R^{22})-NO_2$, $C(R^{22})-CN$ and $C(CN)_2$, wherein

R^{21} is independently selected from the meanings given for R^{13} , R^{14} , and

15

R^{22} is independently selected from the meanings given for R^{11} , R^{12} ,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

20

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

u is 0, 1, 2 or 3, preferably 0, 1 or 2,

25

and


Hal is independently selected from a group consisting of F, Cl, Br and I;

30


and the salts and solvates thereof.

4. Glycinamide derivative according to one of the claims 1 to 3, selected from the compounds of formula IIa, IIb, IIc, IId, IIe, IIg and IIh,


5




10




15



20




25




30


- 172 -



II f




II g




II h

wherein R^8 , p , Y , R^9 and q are as defined in claim 3, and R^{10} is H or as defined in claim 3; and the salts and solvates thereof.

5. Glycinamide derivative according to claim 1 or 2, selected from




25




30

- 173 -

5




10




15

20




25




30

- 174 -

5



10



15

20

25

30

6. Glycinamide derivative according to one of the claims 1 to 5 as a medicament.
7. Glycinamide derivative according to one of the claims 1 to 5 as a kinase inhibitor.
8. Glycinamide derivative according to claim 7, characterized in that the kinases are selected from raf-kinases.
9. Pharmaceutical composition, characterized in that it contains one or more compounds according to one of the claims 1 to 5.
10. Pharmaceutical composition according to claim 9, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 5.
11. Process for the manufacture of a pharmaceutical composition, characterised in that one or more compounds according to one of the

claims 1 to 5 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 5, is processed by mechanical means into a
5 pharmaceutical composition that is suitable as dosageform for application and/or administration to a patient.

12. Use of a compound according to one of the claims 1 to 5 as a
10 pharmaceutical.

13. Use of a compound according to one of the claims 1 to 5 in the treatment and/or prophylaxis of disorders.

14. Use of a compound according to one of the claims 1 to 5 for
15 producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.

15. Use according to claim 13 or 14, characterised in that the disorders are caused, mediated and/or propagated by raf-kinases.
20

16. Use according to claim 13, 14 or 15, characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

17. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is cancer.
25

18. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is noncancerous.
30

19. Use according to claim 13, 14, 15, 16 or 18, characterised in that the noncancerous disorders are selected from the group consisting of

- 176 -

infection, psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

- 5 20. Use according to one of the claims 13 to 17, characterised in that the disorders are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, 10 gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
- 15 21. Use according to one of the claims 13 to 16, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative diseases. 20
22. Use of a compound according to one of the claims 1 to 5 as a raf-kinase inhibitor.
- 25 23. Use according to claim 22, characterised in that the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf-1.
- 30 24. Method for the treatment and/or prophylaxis of disorders, characterised in that one or more compounds according to one of the claims 1 to 5 is administered to a patient in need of such a treatment.
25. Method according to claim 24, characterised in that the one or more compounds according to one of the claims claim 1 to 5 are

- 177 -

administered as a pharmaceutical composition according to claim 9 or 10.

26. Method for the treatment and/or prophylaxis of disorders according to claim 25, characterised in that the disorders are as defined in one of the claims 15 to 21.


27. Method for the treatment according to claim 26, characterised in that the disorders is cancerous cell growth mediated by raf-kinase.

10

28. Method for producing compounds of formula II, characterised in that

a) a compound of formula III

15



wherein

20


L^1 is Cl, Br, I, OH, a reactive esterified OH-group or a diazonium moiety, and R^8 , p , Ar^1 , Y are as defined in claim 3,

is reacted

25

b) with a compound of formula IV,

30



- 178 -

wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^9 ,
 q , X , Ar^2 , R^{10} and r are as defined in claim 3,


5

and optionally

isolating and/or treating the compound of formula II obtained by said
 reaction with an acid, to obtain the salt thereof.

10

29. Compound of formula III,




15

wherein

L^1 is Cl, Br, I, OH, a reactive esterified OH-group or a diazonium
 moiety, and R^8 , p , Ar^1 , Y are as defined in claim 3.

20

30. Compound of formula IV,



25

wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^9 , q , X ,
 Ar^2 , R^{10} and r are as defined in claim 3.

30